MeiraGTx Holdings plc Increase (Decrease) in Accounts Receivable, Related Parties
MeiraGTx Holdings plc (MGTX) reported Increase (Decrease) in Accounts Receivable, Related Parties of $2.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2026-08-13
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for the quarter ending 2026-06-30 was $2.56M, a 59.48% increase year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for the quarter ending 2026-03-31 was $260.00K, a 430.61% increase year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for the quarter ending 2025-12-31 was $194.00K.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for the quarter ending 2025-09-30 was $490.00K, a 82.06% decline year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for fiscal 2025 was $2.34M.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for fiscal 2024 was -$6.33M.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for fiscal 2023 was -$9.97M.
- MeiraGTx Holdings plc increase (decrease) in accounts receivable, related parties for fiscal 2022 was -$1.03M.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 3 month as first filed | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month as first filed | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month as first filed | Increase (Decrease) in Accounts Receivable, Related Parties 12 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.82M 10-Q · filed 2026-08-13 | $3.01M derived: sum of 3 quarters · filed 2026-08-13 | $3.50M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $260.00K 10-Q · filed 2026-05-14 | $454.00K derived: sum of 2 quarters · filed 2026-05-14 | $944.00K derived: sum of 3 quarters · filed 2026-05-14 | $2.55M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $684.00K derived: sum of 2 quarters · filed 2026-03-30 | $2.29M derived: sum of 3 quarters · filed 2026-08-13 | $2.34M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.09M derived: sum of 2 quarters · filed 2026-08-13 | $2.14M 10-Q · filed 2025-11-13 | $851.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.65M 10-Q · filed 2026-08-13 | $361.00K derived: sum of 3 quarters · filed 2026-08-13 | $3.09M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $49.00K 10-Q · filed 2026-05-14 | -$1.24M derived: sum of 2 quarters · filed 2026-05-14 | $1.49M derived: sum of 3 quarters · filed 2026-05-14 | -$7.88M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.44M derived: sum of 2 quarters · filed 2026-03-30 | -$7.93M derived: sum of 3 quarters · filed 2026-03-30 | -$6.33M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$6.64M derived: sum of 2 quarters · filed 2025-11-13 | -$5.03M 10-Q · filed 2025-11-13 | -$15.21M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$9.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$7.76M 10-Q · filed 2025-08-14 | -$17.94M derived: sum of 3 quarters · filed 2025-08-14 | -$28.29M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $1.60M 10-Q · filed 2025-05-13 | -$8.57M derived: sum of 2 quarters · filed 2025-05-13 | -$18.92M derived: sum of 3 quarters · filed 2025-05-13 | -$22.51M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$10.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$20.53M derived: sum of 2 quarters · filed 2025-03-13 | -$24.11M derived: sum of 3 quarters · filed 2025-03-13 | -$9.97M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$10.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$13.94M derived: sum of 2 quarters · filed 2024-11-13 | $198.00K 10-Q · filed 2024-11-13 | -$2.98M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $10.55M 10-Q · filed 2024-08-12 | $7.37M derived: sum of 3 quarters · filed 2024-08-12 | $15.31M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $14.14M 10-Q · filed 2024-05-09 | $10.96M derived: sum of 2 quarters · filed 2024-05-09 | $18.90M derived: sum of 3 quarters · filed 2024-05-09 | $22.28M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $4.76M derived: sum of 2 quarters · filed 2024-03-15 | $8.14M derived: sum of 3 quarters · filed 2024-03-15 | -$1.03M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $7.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $11.32M derived: sum of 2 quarters · filed 2023-11-14 | $2.15M 10-Q · filed 2023-11-14 | $7.24M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$5.79M 10-Q · filed 2022-08-11 | -$701.00K derived: sum of 3 quarters · filed 2022-08-11 | -$1.52M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2022-03-31 | -$9.17M 10-Q · filed 2022-05-12 | -$4.08M derived: sum of 2 quarters · filed 2022-05-12 | -$4.90M derived: sum of 3 quarters · filed 2022-05-12 | $1.20M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $4.28M derived: sum of 2 quarters · filed 2022-03-10 | $10.37M derived: sum of 3 quarters · filed 2022-08-11 | -$16.39M 10-K · filed 2022-03-10 | ||||
| 2021-09-30 | -$818.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.28M derived: sum of 2 quarters · filed 2022-08-11 | -$21.48M 10-Q · filed 2021-11-10 | -$9.81M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-06-30 | $6.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$20.67M 10-Q · filed 2022-08-11 | -$8.99M derived: sum of 3 quarters · filed 2022-08-11 | -$6.40M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$26.76M 10-Q · filed 2022-05-12 | -$15.09M derived: sum of 2 quarters · filed 2022-05-12 | -$12.50M derived: sum of 3 quarters · filed 2022-05-12 | -$16.07M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $11.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $14.27M derived: sum of 2 quarters · filed 2022-03-10 | $10.70M derived: sum of 3 quarters · filed 2022-03-10 | $15.40M 10-K · filed 2022-03-10 | $15.40M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$981.00K derived: sum of 2 quarters · filed 2021-11-10 | $3.73M 10-Q · filed 2021-11-10 | $3.73M 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | -$3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.14M 10-Q · filed 2021-08-11 | $1.14M 10-Q · filed 2020-08-06 | |||||
| 2020-03-31 | $4.71M 10-Q · filed 2021-05-11 | $4.71M 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | $23.89M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |